Jpmorgan Chase & CO Xtant Medical Holdings, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Xtant Medical Holdings, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 111 shares of XTNT stock, worth $41. This represents 0.0% of its overall portfolio holdings.
Number of Shares
111
Previous 112
0.89%
Holding current value
$41
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding XTNT
# of Institutions
30Shares Held
98.2MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA73.1MShares$27.1 Million1.17% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT11.4MShares$4.22 Million0.46% of portfolio
-
Altium Capital Management LP New York, NY7.42MShares$2.74 Million1.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.15MShares$795,8370.0% of portfolio
-
Juniper Investment Company, LLC New York, NY1.32MShares$488,0090.36% of portfolio
About Xtant Medical Holdings, Inc.
- Ticker XTNT
- Exchange NYSE
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 108,226,000
- Market Cap $40M
- Description
- Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healin...